Indoco Remedies credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1,0361,036994672333
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1,0031,003976640319
1.11×1.11×0.98×0.61×0.32×
1.08×1.08×0.96×0.58×0.31×
7.31×7.31×10.01×2.75×1.16×
5.95×7.07×9.84×2.62×1.11×
0.13×0.13×−0.22×4.01×8.61×
50.5%52.6%49.4%37.7%24.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDOCO₹209.50

Indoco Remedies Limited

· Pharma & Health
₹ CrorePeersSAIPARENTPANACEABIOHIKALWINDLASHESTERBIODCALSYNCOMFSOLARAMcap ₹1,934 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Total Debt332.9672.0993.61,035.91,035.9
Net Debt318.5640.4976.51,002.91,002.9
Total Debt/Equity0.320.610.981.111.11
Net Debt/Equity0.310.580.961.081.08
Total Debt/EBITDA1.162.7510.017.317.31
Net Debt/EBITDA1.112.629.847.075.95
Interest Coverage (EBIT/Interest)8.614.01-0.220.130.13
Total Debt/Total Capital %24.4537.7049.3852.6450.49
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.